MeSH term | MeSH ID | Detail |
---|---|---|
Sacroiliitis | D058566 | 1 associated lipids |
Chlamydial Pneumonia | D061387 | 2 associated lipids |
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Katsura Y et al. | Anti-Helicobacter pylori agents. 3. 2-[(Arylalkyl)guanidino]-4-furylthiazoles. | 1999 | J. Med. Chem. | pmid:10425101 |
Mera R et al. | Eradication of Helicobacter pylori infection with proton pump-based triple therapy in patients in whom bismuth-based triple therapy failed. | 1999 | J. Clin. Gastroenterol. | pmid:10405232 |
Horgan SE et al. | Use of a low nutrient culture medium for the identification of bacteria causing severe ocular infection. | 1999 | J. Med. Microbiol. | pmid:10403423 |
Lasko B et al. | Efficacy and safety of oral levofloxacin compared with clarithromycin in the treatment of acute sinusitis in adults: a multicentre, double-blind, randomized study. The Canadian Sinusitis Study Group. | 1998 | J. Int. Med. Res. | pmid:10399110 |
Inoue M et al. | [Susceptibilities of Enterococcus faecium, PRSP and MRSA to RP59500 and their correlations with those to other drugs]. | 1999 | Jpn J Antibiot | pmid:10396687 |
Hafner R et al. | Correlation of quantitative bone marrow and blood cultures in AIDS patients with disseminated Mycobacterium avium complex infection. | 1999 | J. Infect. Dis. | pmid:10395860 |
Tsukamoto T et al. | Biofilm in complicated urinary tract infection. | 1999 | Int. J. Antimicrob. Agents | pmid:10394976 |
Raderer M et al. | Successful symptomatic management of a patient with Ménétrier's disease with long-term antibiotic treatment. | 1999 Jul-Aug | Digestion | pmid:10394031 |
Stewart AK et al. | Lack of response to short-term use of clarithromycin (BIAXIN) in multiple myeloma. | 1999 | Blood | pmid:10391696 |
Tomiyama Y et al. | [The combination therapy of clarithromycin and sparfloxacin for pulmonary Mycobacterium gordonae infection]. | 1999 | Kekkaku | pmid:10386036 |
Houben MH et al. | Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383522 |
Grimley CE et al. | Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383520 |
Sieg A et al. | Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate Helicobacter pylori. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383519 |
Calvet X et al. | Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383508 |
Ducóns JA et al. | Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383507 |
Miwa H et al. | Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383502 |
Huang J and Hunt RH | The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383500 |
Steele-Moore L et al. | In vitro activities of clarithromycin and azithromycin against clinical isolates of Mycobacterium avium-M. intracellulare. | 1999 | Antimicrob. Agents Chemother. | pmid:10383373 |
Hoellman DB et al. | Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents. | 1999 | J. Antimicrob. Chemother. | pmid:10382885 |
Schwartz HI et al. | Twice-daily versus thrice-daily clarithromycin in combination with ranitidine bismuth citrate in the eradication of Helicobacter pylori. | 1999 | Helicobacter | pmid:10382126 |
Realdi G et al. | Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. | 1999 | Helicobacter | pmid:10382124 |
Schubert ML | H. pylori and nonulcer dyspepsia: not guilty as charged. | 1999 | Gastroenterology | pmid:10381939 |
Delle Cave M et al. | Seven days of ranitidine bismuth citrate plus two antimicrobials for Helicobacter pylori eradication. | 1999 | Ital J Gastroenterol Hepatol | pmid:10379492 |
Vakil N | Treatment of H. pylori infection: the reality. | 1998 Mar-Apr | Yale J Biol Med | pmid:10378357 |
Alvarez-Elcoro S and Enzler MJ | The macrolides: erythromycin, clarithromycin, and azithromycin. | 1999 | Mayo Clin. Proc. | pmid:10377939 |
Bamford JT et al. | Effect of treatment of Helicobacter pylori infection on rosacea. | 1999 | Arch Dermatol | pmid:10376693 |
Masa K et al. | Effect of clarithromycin and other macrolides on the sulfoxidation and 5-hydroxylation of lansoprazole in dogs. | 1999 | Biol. Pharm. Bull. | pmid:10375172 |
Behrens R et al. | Dual versus triple therapy of Helicobacter pylori infection: results of a multicentre trial. | 1999 | Arch. Dis. Child. | pmid:10373140 |
Bhasin DK et al. | Helicobacter pylori eradication: comparison of three treatment regimens in India. | 1999 | J. Clin. Gastroenterol. | pmid:10372934 |
Iida H et al. | Hypoglycemia induced by interaction between clarithromycin and disopyramide. | 1999 | Jpn Heart J | pmid:10370402 |
Wimsatt JH et al. | Clarithromycin pharmacokinetics in the desert tortoise (Gopherus agassizii). | 1999 | J. Zoo Wildl. Med. | pmid:10367642 |
Moshkowitz M et al. | The efficacy of omeprazole-based short-term triple therapy in Helicobacter pylori-positive older patients with dyspepsia. | 1999 | J Am Geriatr Soc | pmid:10366173 |
Gooch WM et al. | Loracarbef versus clarithromycin in children with acute otitis media with effusion. | 1999 | Clin Ther | pmid:10363736 |
Fost DA et al. | Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. | 1999 | J. Allergy Clin. Immunol. | pmid:10359882 |
Jacoby EB and Porter KB | Helicobacter pylori infection and persistent hyperemesis gravidarum. | 1999 | Am J Perinatol | pmid:10355915 |
Pilotto A et al. | Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients. | 1999 | J. Gastroenterol. Hepatol. | pmid:10355512 |
Son SW et al. | The response of rosacea to eradication of Helicobacter pylori. | 1999 | Br. J. Dermatol. | pmid:10354058 |
Debets-Ossenkopp YJ et al. | Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. | 1999 | J. Antimicrob. Chemother. | pmid:10350380 |
Champney WS and Tober CL | Molecular investigation of the postantibiotic effects of clarithromycin and erythromycin on Staphylococcus aureus cells. | 1999 | Antimicrob. Agents Chemother. | pmid:10348746 |
Sonnenberg A et al. | Antibiotic therapy of Helicobacter pylori infection reduces healthcare expenditures related to duodenal ulcer. | 1999 | Am J Manag Care | pmid:10345967 |
Dajani AI et al. | One-week triple regime therapy consisting of pantoprazole, amoxicillin and clarithromycin for cure of Helicobacter pylori-associated upper gastrointestinal diseases. | 1999 | Digestion | pmid:10343146 |
Abdul Aal GM et al. | Resolution of gastritis induced by Helicobacter pylori 4-5 weeks after successful eradication of infection using a triple therapy regimen of pantoprazole, amoxycillin and clarithromycin for one week. | 1999 | Digestion | pmid:10343145 |
Nitu IC et al. | Management of liver failure in a haemophilic patient co-infected with human immunodeficiency and hepatitis C viruses. | 1999 | Clin Lab Haematol | pmid:10342075 |
Champney WS and Tober CL | Superiority of 11,12 carbonate macrolide antibiotics as inhibitors of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. | 1999 | Curr. Microbiol. | pmid:10341075 |
Bocheńska-Marciniak M et al. | [Clinical efficacy and safety of spiramycin and clarithromycin in the treatment of outpatients with lower respiratory tract infections]. | 1998 | Pol. Arch. Med. Wewn. | pmid:10335027 |
Le Gars L et al. | Polyarthralgia-arthritis syndrome induced by low doses of rifabutin. | 1999 | J. Rheumatol. | pmid:10332992 |
Carbon C and Poole MD | The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. | 1999 | J Chemother | pmid:10326741 |
Warheker PT et al. | Successful treatment of saccular endophthalmitis with clarithromycin. | 1998 | Eye (Lond) | pmid:10326009 |
Woods GL et al. | Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. | 1999 | J. Clin. Microbiol. | pmid:10325306 |
Vakil N and Cutler A | Ten-day triple therapy with ranitidine bismuth citrate, amoxicillin, and clarithromycin in eradicating Helicobacter pylori. | 1999 | Am. J. Gastroenterol. | pmid:10235192 |